A couple of weeks ago in Black Monday we wrote that
That in turn would be when a treatment is available, which takes us to our next policy action. Remove bureaucratic obstacles. If you listen closely you’ll hear it said that there are no currently approved vaccines or therapies. In fact there are both vaccines and therapies in existence now. Technology isn’t standing in the way; bureaucracy is. The decision whether to try a preventative or treatment should be up to the patient and doctor.
There’s good news on that front, via The New York Times:
The Food and Drug Administration has given emergency approval to a Trump administration plan to distribute millions of doses of anti-malarial drugs to U.S. hospitals, saying it is worth the risk of trying unproven treatments to slow the disease in seriously ill patients.
Freedom works. This is not to say that this or any other specific treatment will cure COVID-19, but there’s no faster way of finding out what helps than trying it on thousands of patients, many of whom might die without treatment. It’s also not to say there isn’t value in gold-standard, randomized, controlled studies, but common sense prevails. Just some of the proposed treatments include a combination of repurposed hyrdoxychloroquine, azithromycin, and zinc sulfate, a combination of danoprevir and ritonavir, and Gilead’s remdesivir. A medical doctor should be qualified to make a determination of what may be worth trying in any individual case, and the FDA action encouragingly reflects that.